Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-10-05
2002-09-24
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S04400A, C514S045000, C536S026900, C536S027200
Reexamination Certificate
active
06455508
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the field of heterocyclic aromatic compounds and nucleosides.
BACKGROUND OF THE INVENTION
Mammalian immune systems contain two major classes of lymphocytes: B lymphocytes (B cells), which originate in the bone marrow; and T lymphocytes (T cells) that originate in the thymus. B cells are largely responsible for humoral immunity (i.e., antibody production), while T cells are largely responsible for cell-mediated immunity.
T cells are generally considered to fall into two subclasses, helper T cells and cytotoxic T cells. Helper T cells activate other lymphocytes, including B cells and cytotoxic T cells, and macrophages, by releasing soluble protein mediators called cytokines that are involved in cell-mediated immunity. As used herein, lymphokines are a subset of cytokines.
Helper T cells are also generally considered to fall into two subclasses, Type 1 and Type 2. Type 1 cells produce interleukin 2 (IL-2), tumor necrosis factor (TNF&agr;) and interferon gamma (IFN&ggr;), and are responsible primarily for cell-mediated immunity such as delayed type hypersensitivity and antiviral immunity. In contrast, Type 2 cells produce interleukins, IL4, IL-5, IL-6, IL-9, IL-10 and IL-13, and are primarily involved in assisting humoral immune responses such as those seen in response to allergens, e.g. IgE and IgG4 antibody isotype switching (Mosmann, 1989
, Annu Rev Imniunol
, 7:145-173).
As used herein, the terms Type 1 and Type 2 “responses” are meant to include the entire range of effects resulting from induction of Type 1 and Type 2 lymphocytes, respectively. Among other things, such responses include variation in production of the corresponding cytokines through transcription, translation, secretion and possibly other mechanisms, increased proliferation of the corresponding lymphocytes, and other effects associated with increased production of cytokines, including motility effects.
Previous application Nos. (09/291903, 09/471513, 60/164365, 60/164366, 60/172097, 60/175111), each of which is incorporated herein by reference, relate to aspects of our recent discoveries involving the effect of various nucleosides (which are defined herein to include derivatives and analogs of native nucleosides) on selectively modulating lymphocyte responses relative to each other. Among other things, we have shown that either of Type 1 and Type 2 responses can be selectively suppressed while the other is either induced or left relatively unaffected, and either of Type 1 or Type 2 responses can be selectively induced while the other is either suppressed or left relatively unaffected. We have also discovered the surprising fact that some nucleosides effective in selectively modulating Type 1 and Type 2 responses relative to one another tend to have a bimodal effect. Among other things, some nucleosides that tend to generally suppress or induce both Type 1 and Type 2 activity at a relatively higher dose tend to selectively modulate Type 1 and Type 2 relative to each other at relatively lower doses.
The effect of other heterocyclic aromatic compounds on selectively modulating lymphocyte responses relative to each other has not been previously studied or documented. We have discovered that the bimodal effect, or selective modulation of Type 1 and Type 2 responses relative to one another, also occurs after administration of other heterocyclic aromatic compounds.
Despite the existence of as-yet undefined mechanisms, we have discovered that enormous potential benefits can be derived from selective modulation of Type 1 and Type 2 responses relative to each other. We have concluded, for example, that specific modulation of Type 1 relative to Type 2 can be useful in treating a wide variety of conditions and diseases, ranging from infections, infestations, tumors and hypersensitivities to autoimmune diseases.
These discoveries are especially significant because modem treatment strategies for many of the above-listed diseases have limited effectiveness, significant side effects, or both. Treatment of autoimmune disease, for example, is frequently limited to palliative measures, removal of toxic antibodies (as in myasthenia gravis), and administration of hazardous drugs including corticosteroids, chloroquine derivatives, and antimetabolic or antitumor drugs, and drugs such as cyclosporines that target immune system cells.
SUMMARY
The present invention is directed to novel heterocyclic aromatic compounds, their therapeutic uses and synthesis.
In one aspect of the invention, there are provided heterocyclic aromatic compounds of Formula 1:
In yet another aspect of the invention, a pharmaceutical composition comprises a therapeutically effective amount of a Formula 1 carboxamidine, or a pharmaceutically acceptable ester or salt thereof admixed with at least one pharmaceutically acceptable carrier.
In still yet another aspect of the invention, a pharmaceutical composition comprises a therapeutically effective amount of a Formula 2 carboxamidine, or a pharmaceutically acceptable ester or salt thereof admixed with at least one pharmaceutically acceptable carrier.
In a further aspect of the invention, a compound according to Formulas 1 or Formula 2 are used in the treatment of any condition which responds positively to administration of the compound, and according to any formulation and protocol which achieves the positive response. Among other things, it is contemplated that compounds of Formula 1 or Formula 2 may be used to treat an infection, an infestation, a cancer, tumor or other neoplasm, giant cell arteritis, or an autoimmune disease.
REFERENCES:
patent: 3798209 (1974-03-01), Witkowski et al.
patent: 3962211 (1976-06-01), Townsend et al.
patent: 3984396 (1976-10-01), Witkowski et al.
patent: 3991078 (1976-11-01), Witkowski et al.
patent: 4093624 (1978-06-01), Revankar et al.
patent: RE29835 (1978-11-01), Witkowski et al.
patent: 4892865 (1990-01-01), Townsend et al.
patent: 64-026593 (1989-01-01), None
DeClercq et al., Antimicrobial Agents and Chemotherapy, vol. 29, No. 3, pp. 482-487 (Mar. 1986).*
Gabrielsen et al., J. Med. Chem., vol. 35, No. 17, pp. 3231-3238 (Aug. 1992).
Ramasamy Kanda S.
Tam Robert
Fish Robert D.
Fish & Associates, LLP
Wilson James O.
LandOfFree
Methods for treating diseases with tirazole and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating diseases with tirazole and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating diseases with tirazole and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2835759